SLXN
NASDAQSilexion Therapeutics Corp
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$2.81-0.01 (-0.36%)
03:45 PM04:00 PM
News · 26 weeks65-47%
2025-12-282026-06-21
Mix3690d
- SEC Filings21(58%)
- Other10(28%)
- Insider4(11%)
- Earnings1(3%)
Latest news
25 items- PRSilexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerCTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany With approvals now secured in Israel and Germany - the two major regulatory jurisdictions in which Silexion sought clearance - the Company is positioned to initiate the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer across both countries First patient dosing expected in the coming weeks at one of the activated Israeli or German sites, subject to completion of standard site activation procedures, including contracti
- SECSEC Form EFFECT filed by Silexion Therapeutics CorpEFFECT - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form 424B3 filed by Silexion Therapeutics Corp424B3 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics to Attend BIO International Convention 2026Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company's Chief Executive Officer, Ilan Hadar, and the Company's Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA. Silexion's management will host one-on-one meetings during the BIO Convention. Interested parties should contact Silexion company representative to arrange a meeting. About Silexion TherapueticsSilexion Therapeut
- SECSEC Form S-3 filed by Silexion Therapeutics CorpS-3 - Silexion Therapeutics Corp (0002022416) (Filer)
- INSIDERCSO and CDO Shirvan Mitchell was granted 6,000 units of Ordinary Shares, increasing direct ownership by 215% to 8,789 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERCFO and Secretary Horenshtein Hadar Mirit was granted 7,500 units of Ordinary Shares, increasing direct ownership by 150% to 12,515 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERChairman and CEO Hadar Ilan was granted 10,000 units of Ordinary Shares, increasing direct ownership by 153% to 16,547 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics CorpSCHEDULE 13D/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form S-8 filed by Silexion Therapeutics CorpS-8 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces 1-for-10 Reverse Share SplitGrand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company's ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on May 29, 2026, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every ten ordina
- SECAmendment: SEC Form 10-K/A filed by Silexion Therapeutics Corp10-K/A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateIsraeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU Clinical Trials Information System Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026 Grand Cayman, May 18, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today provided an update on recent business developments following the release of its financial results for the first quarter ended
- SECSEC Form 10-Q filed by Silexion Therapeutics Corp10-Q - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces Exercise of Warrants for $1 Million Gross ProceedsGrand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company's ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective res
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic CancerGrand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive preclinical findings from an ongoing translational immuno-oncology study evaluating its lead candidate, SIL204, in human KRAS-mutated pancreatic cancer cells. The study demonstrated a statistically significant increase in surface expression of major histocompatibility complex class I (MHC-I), also known as HLA-ABC, following treatment with SIL204 in human pancreatic cancer cells harboring the KRAS G12R mutation, as measured
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical CenterSilexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee approves planned Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking an important clinical site activation milestone at a leading Israeli oncology center; Underscores continued regulatory momentum in preparation for trial initiation Grand Cayman, Cayman Islands, May 13, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage bio
- SECSEC Form EFFECT filed by Silexion Therapeutics CorpEFFECT - Silexion Therapeutics Corp (0002022416) (Filer)
SLXN FAQ
4 questionsWhere does SLXN stock trade?
Silexion Therapeutics Corp (SLXN) is listed on NASDAQ.What sector and industry is SLXN in?
Silexion Therapeutics Corp operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to SLXN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SLXN side-by-side with any of them on Quantisnow.How can I track SLXN on Quantisnow?
Quantisnow aggregates Silexion Therapeutics Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLXN to receive live email and push alerts on every new disclosure.